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BACKGROUND & AIMS: Interleukin (IL)33/IL1F11 is an
important mediator for the development of type 2 T-helper cell
(Th2)–driven inflammatory disorders and has also been
implicated in the pathogenesis of gastrointestinal (GI)-related
cancers, including gastric carcinoma. We therefore sought to
mechanistically determine IL33’s potential role as a critical
factor linking chronic inflammation and gastric carcinogenesis
using gastritis-prone SAMP1/YitFc (SAMP) mice. METHODS:
SAMP and (parental control) AKR mice were assessed for
baseline gastritis and progression to metaplasia. Expression/
localization of IL33 and its receptor, ST2/IL1R4, were charac-
terized in corpus tissues, and activation and neutralization
studies were both performed targeting the IL33/ST2 axis.
Dissection of immune pathways leading to metaplasia was
evaluated, including eosinophil depletion studies using anti-
IL5/anti-CCR3 treatment. RESULTS: Progressive gastritis and,
ultimately, intestinalized spasmolytic polypeptide-expressing
metaplasia (SPEM) was detected in SAMP stomachs, which
was absent in AKR but could be moderately induced with
exogenous, recombinant IL33. Robust peripheral (bone
marrow) expansion of eosinophils and local recruitment of both
eosinophils and IL33-expressing M2 macrophages into corpus
tissues were evident in SAMP. Interestingly, IL33 blockade did
not affect bone marrow-derived expansion and local infiltration
of eosinophils, but markedly decreased M2 macrophages and
SPEM features, while eosinophil depletion caused a significant
reduction in both local IL33-producing M2 macrophages and
SPEM in SAMP. CONCLUSIONS: IL33 promotes metaplasia and
the sequelae of eosinophil-dependent downstream infiltration
of IL33-producing M2 macrophages leading to intestinalized
SPEM in SAMP, suggesting that IL33 represents a critical link
between chronic gastritis and intestinalizing metaplasia that
may serve as a potential therapeutic target for preneoplastic
conditions of the GI tract.
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The link between chronic inflammation and cancer iswell established, with inflammation-associated can-
cers among the most highly represented and frequently
occurring neoplasias worldwide.1,2 Investigation over the
last several years has focused on determining critical
pathways involved in this process, with a number of
candidate molecules identified, including members of the
interleukin (IL) 1 family that are particularly important in
gastrointestinal (GI)-related cancers.3,4 Of these, IL33 plays
a prominent role in intestinal tumorigenesis, both in mouse
models of adenomatous polyposis (ie, ApcMin strain) and
inflammation-associated colorectal cancer, as well as in
patients with colorectal adenocarcinoma.5–7
Less is known regarding the contribution of IL33 to the
development of upper GI cancers, including gastric ade-
nomas, which generally occur as a consequence of chronic
gastritis after prolonged Helicobacter (H) pylori infection or
as a result of autoimmune gastritis.8 As such, while IL33
clearly plays a paramount role in both inflammation and
cancer, a definitive link between IL33-dependent inflam-
mation and carcinogenesis in the GI tract has yet to be
determined.
IL33/interleukin 1 family member 11 (IL1F11) is widely
distributed throughout various organ systems, primarily in
nonhematopoietic cells, but also in cells of hematopoietic
origin, particularly in restricted populations of professional
antigen-presenting cells such as macrophages.9,10 IL33 was
initially associated with type 2 T-helper cell (Th2) immu-
nity, based on expression of its cell-bound receptor, ST2L/
IL1R4, on polarized Th2 lymphocytes9 and more recently,
on group 2 innate lymphoid cells (ILC2s),11 and its ability to
effectively induce M1, but more commonly M2 macrophage
differentiation.12 Importantly, IL33 also potently activates
and induces eosinophil infiltration into mucosal organs that
interface with the external environment, such as the GI and
respiratory tracts.9,13,14
Relevant to the present study, prior reports associate
IL33 with poor prognosis in gastric cancer patients,15 and
in vitro experiments suggest that IL33 confers chemo-
resistance16 and increased invasiveness17 of gastric cancer
cells. Recently, IL33-dependent activation of mast cells was
shown to promote tumor angiogenesis and growth that, in
combination with tumor-associated macrophages, positively
correlates with decreased survival of gastric cancer pa-
tients.18 As such, although evolving, the precise role of IL33
in gastric cancer has not yet been fully elucidated; specif-
ically, how IL33 mechanistically exerts the aforementioned
effects and whether IL33 contributes to the development of
preneoplastic states ultimately leading to gastric cancer.
In fact, chronic inflammatory conditions of the stomach
often result in reactive modifications of the mucosa,
including atrophy of mature acid-secreting cells as new
metaplastic lineages arise. Such metaplastic changes in
epithelial cells increase the risk of developing dysplasia and
gastric cancer.19–21 The initial metaplasia that arises,
concomitant with acid-secreting parietal cell atrophy, is
defined by the existence of antral-like mucous cells within
the body (corpus) of the stomach and is known as spas-
molytic polypeptide-expressing metaplasia (SPEM), or
pseudopyloric metaplasia. SPEM22 is thought to arise from
reprogramming of mature chief cells after parietal cell
loss23–25 and is thus named by the induced expression of
spasmolytic polypeptide (ie, trefoil factor 2 [TFF2]), in
metaplastic cells.23,26–28
In addition to SPEM, the stomach can undergo intestinal
metaplasia,19 which is confirmed by the presence of intes-
tinal lineages such as mucus-secreting goblet cells. Chronic
inflammation can promote the progression of metaplastic
mucosa to a more proliferative phenotype that is at risk for
progression to dysplasia and cancer.29 Experimentally,
SPEM can be chemically induced by L635, a parietal cell-
specific protonophore that generates a cascade of events
leading to oxyntic atrophy, infiltration of activated M2-
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polarized macrophages, and SPEM that can develop intes-
tinal characteristics in mice.30 When this model is used, IL33
promotes IL13-dependent M2 polarization of recruited
macrophages and the development of SPEM.31
In the present study, we evaluate a murine model,
SAMP1/YitFc (SAMP) strain,32 that spontaneously develops
chronic gastric inflammation to uncover potential IL33-
dependent mechanism(s) leading to and downstream of
parietal cell loss and chief cell transdifferentiation that can
result in SPEM and an even more proliferative, intestinal-
ized SPEM. We show that:
1. gastritis-prone SAMP mice progressively develop meta-
plasia leading to advanced SPEM-like features;
2. exogenous recombinant (r)IL33 administration induces
moderate metaplasia and M2 macrophage infiltration in
stomachs of healthy (AKR) mice, and under chronic in-
flammatory conditions, exacerbates and advances
metaplasia-acquiring intestinal characteristics in SAMP;
3. neutralization of IL33 in SAMP with established disease
dampens gastritis and progression of metaplasia/SPEM;
4 IL33 induces potent peripheral eosinophil expansion and
subsequent recruitment into stomachs of treated mice; and
5. eosinophil depletion markedly diminishes M2 macro-
phage infiltration and SPEM-like features in SAMP.
Together, our data suggest that IL33 plays a central role
in the early events leading to SPEM and that during chronic
inflammation, or perhaps under other predisposing condi-
tions that promote lack of immune tolerance, or both, IL33-
dependent eosinophil activation and migration are essential
for this process to occur. As such, targeting the IL33/ST2
axis for therapeutic purposes may be beneficial for the
treatment or prevention, or both, of preneoplastic states
leading to gastric cancer.
Materials and Methods
Mice
Mice were provided through core services supported by the
Animal and Mouse Models Cores of National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Dis-
eases P01 DK091222 and P30 DK097948, respectively.
SAMPxIl33/ mice were developed by backcrossing male
C57BL/6J (B6) mice homozygous for a null allele of Il33
(Il33/)5,33 with female SAMP for 10 generations and vali-
dated by microsatellite analysis comparing SAMP- vs B6-
specific markers. Breeding of F1N10 heterozygous offspring
generated SAMP homozygous Il33/, heterozygous, and
wild-type controls, identified by polymerase chain reaction
(PCR).5,33 Mice were maintained as previously described,34
with all procedures approved by the Case Western Reserve
University Institutional Animal Care and Use Committee.
Tissue Harvest and Histologic/Spasmolytic
Polypeptide-Expressing Metaplasia Assessment
Mice were euthanized and whole stomachs removed and
opened along the greater curvature. Forestomach and antrum
were excised, and the corpus was dissected along the longitu-
dinal plane, with 1 strip each placed in RNAlater (Ambion,
Thermo Fisher Scientific, Waltham, MA) or radio-
immunoprecipitation buffer (Pierce Biotechnology, Rockford,
IL) and maintained at 20C until later RNA and protein
extraction, respectively. The remaining tissue strip was sub-
merged in Bouin’s Fixative Solution (Ricca Chemical Company,
Arlington, TX), 4% paraformaldehyde (PFA) (ChemCruz, Santa
Cruz Biochemicals, Dallas, TX), or methacarn. Bouin’s/PFA- and
methacarn-fixed tissues were rinsed in 70% ethanol after 24
hours or 20 minutes, respectively, processed, paraffin-
embedded, and sectioned at 3 to 4 mm. Specimens were
stained with H&E or Alcian blue/periodic acid–Schiff (PAS)
with optional hematoxylin 7221 (Thermo Scientific Richard-
Allan Scientific, Kalamazoo, MI).
Samples were evaluated by trained GI pathologists (W.X.,
A.O.) in a blinded fashion for gastritis/epithelial alterations and
SPEM/intestinalized SPEM as previously described.30,32 SPEM
was scored by calculating the percentage of cross-sectional
involvement, defined by oxyntic atrophy with loss of parietal
cells and replacement of gastric glands with mucous cell line-
ages staining positive for PAS/Alcian blue.
In Vivo Studies
Experiments were conducted in a blinded manner, with
mice randomized to different interventions using progressive
numeric labeling, the code only known to animal caretakers
and revealed at end of each experiment. Scientific rigor, data
reproducibility, and biological variables were followed, based
on recently published guidelines.35 SAMP and sex- and age-
matched AKR mice were evaluated for baseline gastritis and
progression to SPEM/intestinalized SPEM.30,32 For exogenous
IL33 experiments, 8- to-12-week-old mice were injected
intraperitoneally with rIL33 (33 mg/kg) (Enzo Life Sciences,
Farmingdale, NY) or Hank’s buffered salt solution (vehicle),
daily for 1 week. IL33 neutralization was achieved using a
fusion protein (5 mg/kg, intraperitoneally twice weekly for 4
weeks) consisting of the extracellular domain of mouse soluble
(s)ST2 fused to IgG1-Fc (sSt2-Fc); controls were similarly
administered IgG1-Fc (Dirk E. Smith, Amgen, Inc., Seattle, WA).
Eosinophil depletion was performed using monoclonal anti-
bodies against IL5 and C-C motif chemokine receptor 3 (CCR3)
and controls treated with an isotype IgG.34
Quantitative Reverse-Transcription Polymerase
Chain Reaction and Western Blots
Total RNA was isolated, reverse-transcribed, and quantita-
tive polymerase chain reaction (qPCR) performed as previously
described,34 using specific target gene primers (Supplementary
Table 1) normalized to b-actin or 36B4 and reported as relative
fold-difference among groups, with baseline/controls set arbi-
trarily at 1. Total protein extracts from the corpus were pre-
pared and Western blotting was performed.10,33
Staining With 5-Bromo-2-Deoxyuridine and
Immunohistochemistry
Mice were injected with 5-bromo-2-deoxyuridine (BrdU)
labeling agent (Invitrogen, Carlsbad, CA) 2 hours before
euthanization. Gastric tissues were harvested, fixed in 4% PFA,
and stained following the manufacturer’s instructions (BrdU





Staining Kit; Invitrogen). Immunohistochemistry was per-
formed using a polyclonal goat anti-mouse IL33 IgG (R&D
Systems, Minneapolis, MN), biotinylated Dolichos biflorus
agglutinin (DBA, Vector Laboratories, Burlingame, CA), or a
monoclonal rat anti-mouse major basic protein (MBP) IgG
(clone MT-14.7) (James J. Lee, Mayo Clinic, Scottsdale, AZ), with
negative controls prepared under identical conditions in the
absence of respective primary antibodies.34
Parietal cell/eosinophil counts were calculated by average
intact, nucleated cells positive for DBA/MBP in 10 randomly
selected high-power fields.34 Immunofluorescence for confocal
imaging was performed to detect Griffonia simplicifolia II (GSII),
cluster of differentiation (CD) 44v, clusterin (Clu), CD163, IL33,
gastric intrinsic factor (GIF), and imaged/analyzed by the
Vanderbilt Digital Histology Shared Resource.31
Flow Cytometry
Bone marrow (BM) from femurs/tibias was harvested and
processed as previously described.34 Corpus tissues were
processed into single-cell suspensions.31 Then, 2  106 cells
were stained with LIVE/DEAD Fixable Near-IR Dead Cell Stain
(Thermo Fisher Scientific) and specific antibodies to detect
eosinophils and M2 macrophages (Supplementary Table 2).
Samples were acquired with a BD LSR II flow cytometer and
data analyzed with FlowJo Software (both, Becton Dickinson,
Franklin Lakes, NJ).31,34
Statistical Analyses
Data were analyzed using GraphPad Prism 5 (GraphPad
Software, Inc, San Diego, CA). Selection of appropriate statistical
tests was based on variance and underlying distribution of
data. Global effects between groups were assessed using 1-way
analysis of variance with Bonferroni’s correction for multiple
comparisons. Differences between individual groups were
directly compared using the 2-sample unpaired Student’s t test,
and results are expressed as mean ± SEM, unless otherwise
indicated, with P < .05 considered significant.
Results
Gastritis-Prone SAMP Exhibit Morphologic
Features and a Molecular Profile Consistent With
Intestinalized Spasmolytic Polypeptide-
Expressing Metaplasia
SAMP mice develop chronic, immune-mediated
gastritis with increased severity over time.32 Stomachs
from 20-week-old SAMP show remarkable and progres-
sive parietal cell loss compared with age-matched AKR
controls, which possess abundant parietal cells
(Supplementary Figure 1A). The emergence of prominent
Alcian blue/PAS-stained hyperplastic mucous neck cells in
SAMP highlight the presence of acidic mucins, commonly
found in SPEM and adenocarcinoma,36 but are absent in
AKR (Supplementary Figure 1A). Older SAMP display
intense staining for the mucous marker, GSII lectin, while
colocalization with CD44v or Clu, indicative of SPEM,
shows more intense Clu expression along the gastric
glands compared with AKRs. The presence, albeit subtle,
of Cd44v at the base of gastric glands in 20-week-old
SAMP is also detected but is virtually absent in the other
experimental groups (Supplementary Figure 1B).
Molecular profiling of full-thickness corpus shows a
striking decrease in the expression of genes associated
with oxyntic atrophy and foveolar hyperplasia, including
gastric intrinsic factor (Gif), adenosine-5’-triphosphatase
Hþ/Kþ transporting alpha subunit (Atp4a), and trefoil
factor 1 (Tff1), comparing SAMP vs AKR, particularly in
older mice (Supplementary Figure 2A). During acute oxy-
ntic atrophy, as parietal cells die, chief cells show a rapid
decrease in the zymogen granule maturation transcription
factor (Mist1) and an increase in Tff2.26,37 Although no
differences in Tff2 are detected among experimental
groups, Mist1 is markedly decreased in SAMP vs AKR
(Supplementary Figure 2B). Furthermore, the SPEM
markers, human epididymis protein 4 (He4), Clu, lysozyme
(Lyz), and glutathione peroxidase 2 (Gpx2),29,37 are all
dramatically increased in SAMP with established disease
vs AKR (Supplementary Figure 2C). Importantly, markers
of more advanced, proliferative lesions (intestinalized
SPEM),29,30 including cystic fibrosis transmembrane
conductance regulator (Cftr) and deleted in malignant
brain tumors protein 1 (Dmbt1), are strongly upregulated
in 20-week-old SAMP vs AKR, while the early tumor
shrinkage variant 5 (Etv5) transcription factor is un-
changed (Supplementary Figure 2D).
Increased Circulating Interleukin 33, With Its Most
Bioactive Form Localizing to Gastric M2
Macrophages in SAMP With Advanced
Spasmolytic Polypeptide-Expressing Metaplasia
To test the hypothesis that increased and persistent
exposure to IL33 may be needed for intestinalized SPEM to
occur, we initially measured systemic/circulating IL33,
which is substantially increased in SAMP, even before his-
tologically evident gastritis (at 4 weeks) and dramatically
rises as disease becomes more severe, compared with IL33
in AKR that remains relatively stable (Supplementary
Figure 3). Locally, within nondiseased stomachs of 4-
week-old mice, IL33 is primarily found in foveolar epithe-
lium, almost exclusively localized to nuclei (Figure 1A). In
older mice, AKR retain some epithelial-specific nuclear
expression with scant IL33þ cells within the lamina propria
(LP), while abundant and diffuse IL33 immunoreactivity is
observed in SAMP, also within the LP, as well as at the base
of the mucosa (Figure 1A).
Evaluation of IL33 isoforms reveals less abundant
IL33 in 4-week-old SAMP compared with AKR; however,
in older SAMP, only full-length IL33 (fIL33), representing
its most bioactive 30-kD form,38 is prominently
expressed, whereas other less bioactive forms39,40 are
present in AKR (Figure 1B). In fact, SAMP express mainly
fIL33, whereas the 20- to 22-kD cleaved form (cIL33) is
virtually undetectable but clearly present in AKR
(Figure 1B), suggesting increased release of bioactive
fIL33 in SAMP with established disease. Surprisingly, Il33
in SAMP stomachs is decreased compared with AKR
(Figure 1C), which may be due to high circulating IL33














levels (Supplementary Figure 3) and potential negative
feedback mechanism(s) downregulating IL33’s
bioactivity.
Finally, to identify the cellular source of the considerable
yet diffuse IL33 staining within the gastric submucosa of
older SAMP (Figure 1A), immunofluorescent colocalization
studies were performed, revealing abundant, infiltrating
IL33-expressing CD163þ M2 macrophages that are virtually
absent in noninflamed AKR but can be elicited with rIL33
(Figure 1D). Phenotypic characterization of SAMP gastric
mucosal cells confirm the presence of IL33-producing M2
macrophages (Supplementary Figures 4 and 1E and F), with
Figure 1. Differential IL-33 localization/expression in corpus of gastritis-prone SAMP vs control AKR. (A) Representative
immunohistochemistry images localizing IL33 before inflammation (4 weeks old) and during established disease (20 weeks old)
in SAMP (N ¼ 8). Original magnification 10þ2.0 and 40þ2.0 (insets); scale bars: 100 mm and 50 mm (insets). (B) Repre-
sentative Western blot differentiating bioactive fIL33 from cIL33 (N ¼ 4). (C) Il33 expressed as fold-change vs age-matched
AKR (N ¼ 7–8). mRNA, messenger RNA. *P < .05, ***P < .001. (D) Immunofluorescent colocalization of IL-33 (red) and
CD163 (green) show abundance of IL-33–producing M2 macrophages (yellow), further augmented after rIL33 in AKR (N ¼ 4),
and (E) confirmed by fluorescence-activated cell sorter (N ¼ 6). (F) frequency of IL-33-expressing M2 vs M1 macrophages
(N¼6). Original magnification 20; scale bars: 10 mm and 5 mm (insets). FSC, forward scatter; TNF, tumor necrosis factor.
**P < .01.





an overall dominant M2 vs M1 profile vs AKR
(Supplementary Figure 5).
Exogenous Administration of Interleukin 33
Induces Spasmolytic Polypeptide-Expressing
Metaplasia in Normal (AKR) Mice
One of the original observations regarding IL33’s
bioactivity was its ability to promote epithelial hyperplasia,
mainly in goblet cells, within GI and airway mucosae.9 These
findings were confirmed in stomachs of IL33-treated B6
mice, which results in a Th2/signal transducer and activator
of transcription 3 (STAT3)-driven gastric pathology.41 Aside
from inducing infiltration of IL33-expressing CD163þ M2
macrophages (Figure 1D), acute systemic exposure of IL33
AKR consistently promotes the gross anatomic appearance
of thickened gastric mucosal folds that are absent in vehicle-
treated mice (Figure 2A). Histologic evaluation of these folds
reveals striking alterations, including overall hypertrophy of
the gastric mucosa, epithelial hyperplasia, as well as oxyntic
atrophy, while parietal and chief cells remain relatively
intact in vehicle-treated AKR (Figure 2A). Interestingly,
although exogenous IL33 results in only 25% of AKR dis-
playing significant gastritis, increased epithelial hyperplasia
suggests its contribution to inducing mucous neck cell hy-
perplasia and metaplasia (Figure 2B).
The presence of metaplasia is further characterized by
prominent proliferation of cells within the gastric glands,
demonstrated by a greater number of BrdUþ cells, along the
neck and at the base of gastric glands (Figure 2A, right
Figure 2. IL33 administration to healthy AKR induces striking gastric mucosal alterations. (A) Representative photographs of
bisected stomachs, highlighting presence of gastric mucosal folds (black arrows), and photomicrographs of corpus displaying
parietal cell (white arrowheads) atrophy, loss of chief cell (white arrows) differentiation, hyperproliferation of mucus-producing
cells (black arrows), and active proliferation of BrdUþ mucous neck cells after rIL33; original magnification 10 and 40
(insets); scale bars: 100 mm and 50 mm (insets). (B) Quantitation of gastric inflammation and epithelial hyperplasia. (C)
Representative photomicrographs show the appearance of acidic mucins by Alcian blue/PAS-staining (arrows; parietal cells
indicated by arrowheads), and increased presence/intensity of GSII lectin (green) and CD44v (red) after rIL33; original
magnification (left-to-right) 20þ1.25, 40þ1.25, 20, and 40 (insets); scale bars: 100 mm and 50 mm (insets). (D) Semi-
quantitative assessment of SPEM (n ¼ 13-16). **P < .01, ****P<.0001.














panels), and Alcian blue/PAS staining, highlighting the
appearance of hyperplastic acidic mucin-producing neck
cells, comparing IL33- vs vehicle-treated AKRs (Figure 2C).
Finally, accumulation of GSII lectin (a surrogate for
MUC6 expression) colocalizing with CD44v at the base of
glands in treated AKR (Figure 2C), indicating chief cells
transdifferentiation,42 also supports the development of
IL33-dependent SPEM (Figure 2D), but for the most part, in
the absence of inflammation.
Consistent with oxyntic atrophy, molecular profiling
shows that Gif and Atp4a are downregulated in corpus tis-
sues from IL33-treated AKR (Figure 3A), and while Tff1
shows a trend toward decreased expression, Tff2 is strongly
upregulated after short-term IL33 exposure (Figure 3A),
further indicating the occurrence of IL33-induced chief cell
transdifferentiation leading to SPEM. Additionally, He4 and
Clu are consistently upregulated after rIL33 (Figure 3B);
however, only Cftr is considerably increased for the
intestinalized SPEM markers assayed (Figure 3C), suggest-
ing that IL33 has a prominent effect on the development of
SPEM, but to progress to a more advanced intestinalized
phenotype, a longer, more chronic exposure to IL33 may be
needed. Interestingly, exogenous IL33 does not affect Il1rl1
(ST2L), encoding the signaling receptor for IL33, but Il1rl1
(sST2), encoding soluble ST2, an IL33-specific decoy re-
ceptor,43 is markedly increased and Il33 is significantly
decreased (Figure 3D), which is similar to what is observed
in SAMP with established disease and may represent a
negative feedback response after rIL33.
Blockade of Interleukin 33 Signaling Dampens
Spasmolytic Polypeptide-Expressing Metaplasia
Progression in SAMP Mice
To test whether IL33 neutralization is effective in
dampening or reversing intestinalized SPEM, we admin-
istered sST2-Fc to SAMP with established disease.
Treatment with sST2-Fc reduces expression of CD44v and
does not appear to change GIF compared with vehicle
controls but has a significant impact on diminishing the
number of IL33-producing CD163þ M2 macrophages as
well as GSII expression (Figure 4A, right panels). Histo-
logically, global improvement is evident in regards to
epithelial architecture and gland structure, with
decreased Alcian blue/PAS-stained cells, indicating
diminished production of acidic mucins. A substantially
increased census of cells positive for the parietal cell-
specific marker, DBA, is also observed, consistent with
morphology of parietal cell precursors (Figure 4A and B),
which dramatically arise during restitution from SPEM.44
Histologic evaluation shows a 57% decrease in epithelial
hyperplasia after IL33 blockade (Figure 4C), suggesting
Figure 3.Molecular profiling indicates overt metaplasia in AKR corpus after acute exposure to IL33. Relative transcript levels
of (A) Gif, Atp4a, Tff1, and Tff2, (B) He4 and Clu, (C) Cftr, Dmbt1, and Etv5, and (D) Il33, and Il1rl1 variant 1 (ST2L) and 2 (sST2)
after rIL33. Data are expressed as fold-change vs vehicle controls (N ¼ 8). mRNA, messenger RNA. *P < .05, **P < .01, ***P <
.001.





restorative epithelial processes toward normal
homeostasis.
Histology images also show that overall gastric inflam-
mation is visibly decreased after IL33 blockade vs control,
confirmed by reduction in total inflammatory scores
(Figure 4D). Of note, the primary component driving total
inflammation downward in sST2-Fc–treated SAMP is
chronic inflammation, which decreases by 41%, and not
acute inflammation, which remains relatively unchanged
between experimental groups (Figure 4D).
Peripheral Expansion and Local Recruitment of
Eosinophils Are Dramatically Increased in SAMP
With Advanced Spasmolytic Polypeptide-
Expressing Metaplasia and Rely on Interleukin 33
We previously reported that eosinophils play a central
role in mediating chronic, Th2-driven ileitis that is
dependent on intestinal IL33 induced by the gut micro-
biome.34 In the present study, we found that expansion of
peripheral BM-derived eosinophils, defined as CD11bþSi-
glec-Fþ cells (Supplementary Figure 6), is already present
in 4-week-old SAMP, before the appearance of gastritis,
compared with age-matched AKR (Figure 5A). This trend
is consistent with what was previously observed in older
SAMP,34 when intestinal-like metaplasia is fully estab-
lished, and is increased vs 4-week-old SAMP. Locally,
baseline presence of eosinophils identified by MBP, one of
the most prevalent proteins specifically-produced by eo-
sinophils,45,46 is detected in young SAMP and also found in
equal numbers in age-matched AKR (Figure 5B). As dis-
ease progresses, the number of infiltrating MBPþ eosino-
phils greatly increases, first appearing at the margination
between the submucosa and muscularis mucosa and then
collecting at the base of the gastric glands with infiltrates
percolating upwards throughout the LP vs AKRs, wherein
eosinophils are scarce and sparsely detected (Figure 5B).
Quantitatively, MBPþ eosinophils are clearly evident in
SAMP corpus as intestinalizing SPEM progresses, showing
a 4-fold increase by 20 weeks compared with AKR
(Figure 5B).
These results indicate that systemic expansion of eo-
sinophils and their recruitment into gastric tissues occurs
early and is sustained in SAMP with advanced intestinalized
SPEM. Significant abrogation of BM-derived eosinophils
(Figure 5A) and subsequent decreased recruitment into the
gastric mucosa of SAMP lacking IL33 (SAMPxIl33/)
Figure 4. Neutralization of IL33 attenuates chronic gastritis and intestinalized SPEM in SAMP. (A) Representative photomi-
crographs of corpus stained with H&E, Alcian blue/PAS, and DBA after sST2-Fc (left panels). Immunofluorescence for GIF
(blue) remains relatively unchanged, but CD44v (green) and GSII-lectin (red/blue) are decreased, and IL33 (red)/CD163 (green)
shows marked reduction of IL33-producing M2 macrophages (yellow) after sST2-Fc (right panels). Original
magnification 20þ1.25; scale bars: 100 mm. (B) Parietal cell numbers per high-power field (HPF) (arrows, panel A), (C)
epithelial hyperplasia, and (D) gastric inflammation after sST2-Fc (N ¼ 9–11). *P < .05, **P < .01.



















compared with wild-type littermates (SAMPxIl33þ/þ)
(Figure 5C) confirm the early reliance on IL33 for these
effects.
Eosinophil expansion, in fact, can be dramatically eli-
cited, particularly in the periphery, in healthy AKR after
acute (1 week) IL33 administration. Likewise, aside from
the striking mucosal epithelial alterations described above
(Figure 2), IL33 also promotes a trend of eosinophil
recruitment into the corpus of treated AKR (Figure 5D).
These results indicate that in the absence of inflammation,
exogenous IL33 induces robust systemic expansion, and to a
lesser extent, local recruitment of eosinophils into the
gastric mucosa. Interestingly, IL33 blockade in SAMP with
established disease does not affect expansion of BM-derived
eosinophils (Figure 5A) or local recruitment of MBPþ eo-
sinophils (Figure 5E), indicating that once these processes
are induced, particularly in mice exposed to chronic in-
flammatory conditions, they cannot be reversed.
Eosinophil Depletion Effectively Reduces
Gastritis, Infiltration of M2 Macrophages, and
Intestinalized Spasmolytic Polypeptide-
Expressing Metaplasia
Because IL33 blockade is effective in dampening both
infiltration of CD163þ M2 macrophages as well as intestinal-
like metaplasia, but not recruitment of eosinophils in SAMP,
we tested whether earlier intervention of eosinophil
depletion has downstream effects on advanced intestinal-
ized SPEM. As such, 14-week-old SAMP were treated with
antibodies against CCR3 and IL5, alone and in combination,
previously shown to effectively deplete eosinophils.34,47,48
Eosinophil depletion was confirmed in both peripheral BM
and corpus tissues (Supplementary Figures 7A and 6A, left
panels), with histologic evaluation showing global
improvement in restoring normal epithelial architecture,
reducing the presence of cellular immune infiltrates, and
decreasing overall inflammation within the LP and hyper-
plasia of muscle wall layers in mice treated with anti-IL5
and anti-CCR3, alone and in combination, vs IgG-treated
controls (Figure 6A and C). Eosinophil depletion is also
able to effectively decrease the presence of infiltrating IL33-
expressing M2 macrophages (Figure 6A and D and
Supplementary Figure 7B) and potently reduces gene
expression of M2-associated molecules (Supplementary
Figure 7C), but does not affect epithelial-derived IL33
(Supplementary Figure 7D).
Importantly, CD44v colabeling with GSII and GIF reveals
that while no dramatic differences are observed in GSII
among experimental groups, increased intensity of GIF is
noted, particularly in SAMP treated with anti-IL5 or com-
bination anti-IL5/anti-CCR3 vs controls, indicating at least
partial reversal of oxyntic atrophy (Figure 6A, right panels).
Interestingly, the decreased Mist1 seen during SPEM is
dramatically reversed after eosinophil depletion
(Figure 6E), suggesting eosinophil-dependent chief cell
transdifferentiation during SPEM. Taken together, these
results indicate an essential role for eosinophils in the
development of intestinalized SPEM.
Discussion
Increasing evidence confirms the importance of the
IL33/ST2 axis in the development of gastritis and gastric
cancer; in this context, IL33 is an ideal candidate to link
these two processes. However, although several studies
have reported associative findings in patients, correlating
increased IL33 with intestinal-type gastric cancer18 and
poor prognostic factors,15,49 less is known regarding specific
IL33-dependent mechanisms leading to these pathologies.
Based on the published literature and data from the present
study, we propose a working hypothesis regarding the
mechanistic role of IL33 in promoting SPEM progression
and the gastritis-metaplasia-dysplasia-carcinoma sequelae
in which eosinophils play a central role.
Some consider SPEM/intestinalized SPEM is a manda-
tory step for dysplasia, and eventually carcinoma, to pro-
ceed.50 Once established, intestinalized SPEM or intestinal
metaplasia, or both, may not be reversible in the presence of
inciting factors such as chronic inflammation.51 In fact,
along with distinct gastric epithelial changes, an essential
component to attain intestinal-like characteristics is non-
resolving chronic inflammation, often thought to be depen-
dent on H pylori status.51,52 In this setting, IL33 represents a
critical mediator for SPEM/intestinalized SPEM to manifest,
considering its ability to both potently stimulate epithelial
proliferation and metaplasia as well as induce and sustain
chronic Th2-driven inflammation.
Our data show that the most prevalent form of IL33 in
SAMP with established disease is bioactive fIL33, which is
released during chronic inflammation, with minimal pres-
ence of the less bioactive cleaved form (cIL33)38–40 that is
more highly expressed in uninflamed AKR stomachs. In
uninflamed young mice (AKR/SAMP) and older AKR, nu-
clear sequestration occurs within gastric epithelial cells,
serving as reservoirs for IL33 that is readily available for
immediate release upon exposure to appropriate stimuli.18
In fact, under homeostatic conditions, the primary role of
IL33 in the GI tract is believed to be epithelial repair and
restitution and to promote overall mucosal wound
healing.33,53
Interestingly, we found that at the transcript level, Il33 is
significantly decreased in SAMP compared with AKR, which
likely reflects a negative feedback mechanism in response to
high systemic IL33. In line with this finding, Il33 is also
=
Figure 5. Early IL33-dependent peripheral expansion and increased eosinophil recruitment to SAMP stomachs. (A) Percent-
ages of BM-derived eosinophils (EOS), and representative immunohistochemistry photomicrographs of corpus from (B) SAMP
vs AKR, (C) SAMPxIl33/ vs wild-type littermates, (D) IL-33- vs vehicle-treated AKR, and (E) sST2-Fc- vs IgG-treated SAMP,
stained for MBP and eosinophil counts (N ¼ 4-10). HPF, high-power field. Original magnification 10þ1.25; scale bars: 100
mm. **P < .01, ***P < .001.














Figure 6. Eosinophil depletion reduces gastritis, M2 macrophage recruitment, and SPEM in SAMP. (A) Representative pho-
tomicrographs of corpus stained (left-to-right): for MBP (eosinophils), with H&E, and by immunofluorescence for IL33- (red)
expressing CD163þ (green) M2 macrophages (yellow), showing reduction after anti-IL5, anti-CCR3 or combination anti-IL5/
CCR3, and for GSII (green), CD44v (red) and GIF (blue) showing specific increase in GIF (arrowheads), suggesting protec-
tion from oxyntic atrophy. Original magnification 20 and 40 (insets); scale bars: 100 mm, 50 mm (insets). Quantitation of
gastric (B) eosinophils, (C) inflammation, (D) IL33-expressing M2 macrophages, and (E) Mist1 after eosinophil depletion. Data
are representative of 3 experiments (N ¼ 7-8 per experiment). *P < .05, **P < .01; ***P < .001; ****P < .0001.





decreased after exogenous IL33 administration, whereas the
Il1rl1 variant coding for sST2 (soluble decoy receptor) is
greatly increased, which together serve to downregulate
overall IL33 bioactivity.
The present study also introduces the SAMP mouse strain
as a model of intestinalized SPEM that develops spontaneously
and progresses in severity, without chemical, genetic, or
immunologic manipulation. These mice provide an ideal tool to
investigate the natural course of disease and a convenient
system to test potential preclinical therapies for preneoplastic
conditions that may lead to gastric cancer, in which preventive
and therapeutic strategies can both be effectively implemented.
Using a therapeutic approach, we found that IL33
neutralization by sST2-Fc administration is effective at
reversing intestinalized SPEM, primarily by targeting the
epithelial compartment and reducing IL33-dependent
epithelial alterations, which are hallmark features of meta-
plasia. In addition, IL33 blockade decreases the severity of
chronic gastritis and the presence of M2 macrophages,
which are also characteristic of metaplasia and progression
to intestinalized SPEM.31
Importantly, using SAMP, we not only demonstrate the
essential role for IL33 in the development of intestinal-like
metaplasia but also that the IL33/ST2 axis is important for
several steps throughout this process. For example, IL33
clearly has direct effects on epithelial cells. Indeed, epithelial
alterations within the GI tract were among the initial aber-
rancies described after healthy mice were exposed to high
levels of IL33.9 We and others41 confirmed these observa-
tions in the stomach, showing that rIL33 induces severe
oxyntic atrophy and upregulates specific markers of SPEM.
Alternatively, IL33 also has profound effects on the gastric
immune compartment, promoting, for example, vigorous
infiltration of eosinophils and M2 macrophages,31 further
perpetuating a chronic inflammatory state. Importantly,
prolonged and elevated levels of IL33 have the ability to
sustain chronic inflammation in the stomach, which is
essential for intestinal metaplasia to advance to gastric
cancer.
The results of our study also underscore the importance
of eosinophils in the development of intestinal-like meta-
plasia and that IL33 plays a critical role in the systemic
expansion and early recruitment of eosinophils into the
gastric mucosa of SAMP as well as AKRs treated with rIL33.
Previously, eosinophils in gastric metaplasia and cancer
development have been proposed to have both pathogenic
as well as protective functions. A prior study investigating
early gastric cancers demonstrated the presence of tumor
stromal eosinophils with morphologic evidence of activation
as well as tumor cells in intimate contact with activated
eosinophils with focal cytopathic changes.54
Gastric carcinomas have also been reported to express
eosinophil-associated chemotactic cytokines, including IL2,
IL5, and granulocyte-macrophage colony–stimulating factor,
with expression of granulocyte-macrophage colony–
stimulating factor appearing to be specific for signet ring
carcinoma cells.55 On the other hand, in support of a pro-
tective function, high preoperative eosinophil counts were
found to correlate with prolonged survival after surgery,56
and the-28G polymorphism in the promoter region of the
eosinophil chemoattractant RANTES (regulated upon acti-
vation normal T cell expressed and secreted) is associated
with a reduced risk of developing severe intestinal
metaplasia.57
Nonetheless, while our results indicate that eosinophils
play an important role during early events leading to
gastritis/metaplasia, one can certainly speculate that other
IL33-responsive innate immune cell populations may also
contribute. Our data show that IL33 can promote local
recruitment of M2 macrophages that themselves are potent
producers of IL33. These findings are in line with previous
reports demonstrating the ability of IL33 to increase overall
macrophage numbers in the stomach and to polarize them
to an alternatively activated M2 phenotype, albeit in the
periphery (peritoneum),41 and that M2 macrophages are
dramatically reduced in IL33-deficient mice in which
advanced SPEM has been elicited, but that can also be
rescued by administering rIL13.31
Our findings in SAMP, however, indicate that M2
macrophage infiltration is likely downstream of eosinophil
activation and recruitment because eosinophil depletion,
similar to systemic IL33 blockade, has a significant impact
on reducing the infiltration of gastric M2 macrophages that
also happen to produce IL33. Interestingly, however,
eosinophil depletion does not appear to have an effect on
IL33 expression in the gastric epithelium of SAMP. In
contrast, L635-induced SPEM does not appear to require
eosinophils,31 which may simply reflect differences in
inciting factors between the 2 models (ie, chemical obliter-
ation of parietal cells vs chronic, nonresolving
inflammation).
An alternative hypothesis is that ILC2s are also an IL33-
responsive innate immune cell population that can affect
SPEM. ILC2s have not been detected or isolated from gastric
tissues until recently, when Li et al58 reported the preva-
lence of GATA-3þLin cells in tumors of patients with H
pylori-associated gastric cancer. Of note, and counterintui-
tive to this finding, Buzzelli et al41 showed that IL33 is
rapidly induced after acute H pylori infection but sup-
pressed in chronic infection. However, in the former study,
it is unclear what the IL33 levels were, whether they
correlated with GATA-3þLin ILC2 frequency, and whether
IL33 exhibited temporal changes during early vs late stages
in different types of gastric cancers. In the latter study, acute
vs chronic H pylori infection was defined as 1 and 7 days vs
2 months, which may not reflect chronic infection, especially
in gastric cancer-susceptible individuals.
Although indirect evidence suggests emergence of
gastric ILC2s in IL33-treated mice,41 we recently reported
increased ILC2s after L635-dependent acute gastric
injury.59 Similarly, preliminary data in SAMP mice also show
an increased frequency, albeit quite low, of ILC2s vs AKR
(Supplementary Figure 8); however, whether ILC2s
contribute to the SAMP gastric phenotype is unknown. On
the basis of studies characterizing SAMP lacking T/B cells,
but with intact ILC function (ie, SAMPxRag2/ strain), ILCs
likely play a negligible role in SPEM development because
these mice, without the ability to mount adaptive immune














responses and sustain a chronic inflammatory state, have
virtually normal stomachs (Supplementary Figure 8).
Finally, yet another IL33-responsive innate immune cell
population (ie, mast cells) has been recently implicated in
the development of gastric cancer in gp130F/F mice, specif-
ically through mobilization of macrophages.18 Although
similar to early IL33-dependent activation of eosinophils
upstream of macrophage recruitment, the precise temporal
involvement of mast cells and their interaction(s) with other
mucosal populations to promote events leading to intestinal
metaplasia and gastric cancer is unclear.
Taken together, the present study underscores a crit-
ical role for IL33 in the development of chronic inflam-
mation and metaplasia in the stomach and implicates
eosinophils as an early IL33-responsive innate immune
cell population that participates in the complex orches-
tration leading to SPEM/intestinalized SPEM. As such,
targeting the IL33/ST2 axis for future therapeutic mo-
dalities to interrupt the early initial events leading to
gastritis and metaplasia and potentially reversing intes-
tinalizing SPEM may prove to be beneficial for the pre-
vention or treatment, or both, of patients susceptible to
gastric cancer.
Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at https://doi.org/10.1053/
j.gastro.2020.09.040.
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Supplementary Figure 1. Evidence of advanced intestinalized SPEM in stomachs of gastritis-prone SAMP mice. (A)
Representative histologic image of 4-week-old SAMP shows early hyperproliferation of gastric glands compared with age-
matched AKR (left panels), while in 20-week-old SAMP, Alcian blue/PAS staining highlights acidic mucin-secreting cells
(arrows) replacing parietal (arrowheads) and chief cells as SPEM progresses, which is absent in age-matched AKR (right
panels). Original magnification 20þ1.25; scale bars: 100 mm. (B) Representative immunofluorescent images of full-thickness
corpus from 4-week-old SAMP display early, aberrant staining of GSII (green) and Clu (red), characteristic of SPEM (left lower
panels) compared with age-matched AKR (left upper panels) that becomes more evident in 20-week-old SAMP with estab-
lished gastritis, with clear abundance of GSIIþ cells and increased CD44v and Clu (both red), localizing to base of gastric
glands (arrows, right lower panels) compared with age-matched AKR controls (right upper panels). Original magnification 20;
scale bars: 100 mm.
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Supplementary Figure 2.Molecular profiling indicates advanced SPEM in SAMP corpus that progresses with age. Relative
expression of (A) Gif, Atp4a, and Tff1, (B) Tff2 and Mist1, (C) He4, Clu, Lyz, and Gpx2, and (D) Cftr, Dmbt1, and Etv5 in young
SAMP vs SAMP with established disease and vs age-matched AKR controls. Data are expressed as fold-change vs 4-week-
old AKR (with mean arbitrarily set as 1) (N ¼ 6-9). mRNA,2messenger RNA. *P < .05, **P < .01, ***P< .001 vs age-matched
AKR; ##P < .01, ###P < .001 vs 4-week-old AKR/SAMP.
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Supplementary Figure 3. Increased circulating levels of IL33
in SAMP mice. Serum levels of total IL33 protein in 4-, 10-
and 20-week-old SAMP vs age-matched control AKR (N ¼ 3-
6). *P < .05, ***P < .001 vs age-matched AKR; #P<0.05 vs 4-
week-old SAMP.
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Supplementary Figure 4.Gating strategy for distinguishing M1 vs M2 macrophages by flow cytometry. Representative 2-
dimensional dot plots (shown here for BM) for SAMP depict, from left-to-right: (1) side scatter (SSC) vs forward scatter
(FSC) (gating on general cells), (2) FSC area (FAC-A) vs FSC height (FSC-H) (gating on singlets), (3) SSC area (SSC-A) vs live/
dead (gating on live cells), (4) CD11b vs SSC-A (gating on granulocytes), (5) Ly6G vs SSC-A (gating on Ly6G cells), (6) CD163
vs F4/80 (gating on macrophages, Mph), and (7) tumor necrosis factor (TNF) vs major histocompatibility complex (MHC) II
(gating on M1 macrophages), and Arg1 vs CD163 (gating on M2 macrophages).
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Supplementary Figure 5. Strong prominence of M2- vs M1-
associated gene markers expressed in macrophages from
SAMP vs AKR mice. Relative transcript levels of M1- vs M2-
associated molecules (defined in Sica and Mantovani, Trends
Immunol 2002 DOI: 10.1016/s1471-4906(02)02302-5; and
Murray, Immunity 2017 DOI: 10.1146/annurev-physiol-
022516-034339) in isolated macrophages from 10-week-old
SAMP, normalized by 36B4 and expressed as percentage
fold-change of age-matched AKR controls. Data are pre-
sented as mean ± SD (N ¼ 6).
Supplementary Figure 6. Gating strategy for detecting eosinophils (EOS) by flow cytometry. Representative 2-dimensional
dot plots (shown here for BM) for control AKR depict, from left-to-right: (1) side scatter (SSC) vs forward scatter (FSC) (P1,
gating on general cells), (2) FSC area (FSC-A) vs FSC height (FSC-H) (P2, gating on singlets), (3) SSC area (SSC-A) vs live/dead
(gating on live cells), and (4) CD11b vs Siglec-F (gating on eosinophils).
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Supplementary Figure 7. Eosinophil (EOS) depletion is effective in decreasing peripheral (BM) and local (gastric) eosinophils,
and reduces M2 macrophages and expression of M2-associated genes in SAMP stomachs. (A) Frequency of peripheral (BM)-
derived eosinophils (left panel) and eosinophil count (right panel), (B) M2 macrophage frequency (left panel), and M2 macrophage
count (right panel, defined as IL-33þCD163þ cells shown in Figure 6A, middle panels) in SAMP corpus after eosinophil depletion
by administration of anti-IL5 and anti-CCR3, alone and in combination, vs IgG-treated controls (N ¼ 4-9). (C) Relative transcript
levels of M2-associated molecules, normalized by 36B4 and expressed as fold-change vs IgG-treated controls (with mean set
arbitrarily as 1) (N ¼ 6). mRNA, messenger RNA. (D) Representative immunohistochemistry images localizing IL33 (N ¼ 4).
Original magnification 10þ1.25; scale bars: 100 mm. *P < .05, **P < .01, ***P < .001, ****P < .0001.
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Supplementary Figure 8. Evidence that aberrant adaptive immune responses, and not increased ILC2 frequency, is essential
for development of gastritis/SPEM in SAMP mice. Corpus tissues were excised from stomachs of SAMP and AKR and
processed into single-cell suspensions for flow cytometric analysis of ILC2s using the following gating strategy: (A) live cells
were gated on CD45þ, then on CD127þ cells negative for lineage markers CD3 (T cells), CD11c (dendric cells), B220 (B cells),
CD11b (myeloid cells), Ly6g, and Ter-119 (granulocytes), and positive for the transcription factor GATA3, (B) with ILC2s re-
ported as percentages and absolute numbers (N ¼ 3-7). *P < .05, **P < .01. (C) Total inflammation (left panel) and hepithelial
hyperplasia (right panel) in corpus from SAMP  Rag2/ mice vs wild type controls (N ¼ 7-15). *P < .05, **P < .01,
***P < .001.
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